NKTR analyst estimates
Nektar (NKTR) analyst ratings, the average price target and its range, and every firm's latest call.
NKTR analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 12, 2026 | UBS | UBS Starts Nektar Therapeutics (NKTR) at Neutral | $53.00 |
| Oct 12, 2026 | Leerink Partners | Nektar initiated with an Outperform at Leerink | $130.00 |
| Oct 1, 2026 | Jefferies | Nektar selloff after rezpegaldesleukin data 'unwarranted,' says Jefferies | $150.00 |
| Sep 23, 2026 | Wedbush | Nektar price target lowered to $50 from $80 at Wedbush | $50.00 |
| Jul 22, 2026 | Canaccord Genuity | Nektar initiated with a Buy at Canaccord | $153.00 |
| May 11, 2026 | Wedbush | Nektar price target lowered to $80 from $95 at Wedbush | $80.00 |
| May 8, 2026 | Piper Sandler | Nektar price target raised to $192 from $105 at Piper Sandler | $192.00 |
| Apr 21, 2026 | Wedbush | Nektar price target raised to $95 from $70 at Wedbush | $95.00 |
| Apr 20, 2026 | H.C. Wainwright | Nektar price target raised to $185 from $165 at H.C. Wainwright | $185.00 |
| Mar 13, 2026 | Oppenheimer | Nektar Therapeutics (NKTR) PT Raised to $140 at Oppenheimer | $140.00 |
| Feb 10, 2026 | H.C. Wainwright | Nektar price target raised to $165 from $135 at H.C. Wainwright | $165.00 |
| Feb 10, 2026 | BTIG | Nektar price target raised to $151 from $118 at BTIG | $151.00 |
| Jan 26, 2026 | Piper Sandler | Piper Sandler on Nektar Therapeutics (NKTR): 'We See a Substantial Opportunity Into These De-Risked Data' | $105.00 |
| Dec 16, 2025 | Oppenheimer | Nektar price target raised to $115 from $98 at Oppenheimer | $115.00 |
| Dec 16, 2025 | H.C. Wainwright | Nektar price target raised to $135 from $120 at H.C. Wainwright | $135.00 |
- 13 firms rate NKTR: 9 buy, 4 hold, 0 sell.
- The average price target is $121.33 from 6 analysts, from $50.00 to $192.00.
Updated 2026-11-02 23:59 UTC